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Inflammatory cytokines can impair the skin barrier, 
but the question as to whether barrier alterations af-
fect keratinocyte immune responses remains unanswe-
red. The aim of this study was to investigate whether 
immune-mediated skin inflammation differs between se-
vere atopic dermatitis patients with or without filaggrin 
mutation. The levels of filaggrin, inflammatory T helper 
2 polarizing cytokines (thymic stromal lymphopoietin 
(TSLP) and interleukin 33 (IL-33)) and chemokine (C-C 
motif) ligand 27 (CCL27), histological severity markers, 
T-cell and dendritic cell counts in biopsies from lesional 
skin of severe atopic dermatitis patients with and wit-
hout filaggrin mutation and healthy skin were quantified 
by immunohistochemistry. The results were confirmed 
by quantitative PCR analyses. No significant differences 
were found between the 2 patient groups. Expression of 
atopic dermatitis-specific cytokines showed significant 
correlation with histological severity. These findings 
suggest that the immune-mediated skin inflammation 
(represented by keratinocyte-derived factors, T-cell and 
dendritic cell counts) is similar in the 2 patient groups 
with severe atopic dermatitis, and that immune activa-
tion is connected to the severity of the disease rather 
than to the origin of barrier alterations. Key words: 
atopic dermatitis; filaggrin; immunohistochemistry; in-
nate immunity; thymic stromal lymphopoietin.
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Atopic dermatitis (AD) is a chronic inflammatory skin 
disease, which is often accompanied by other allergic 
diseases and impaired quality of life (1–5). Previous 
studies have shown that AD is a Th2-mediated disease 
and have revealed the simultaneous presence of T-help-
er 1 (Th1) and Th22 cells in the chronic phase of skin 
inflammation (6). In addition to the altered adaptive 
immune functions, dysregulated innate immune and 
skin barrier mechanisms have also been studied (7–9). 
A growing body of evidence supports the hypothesis that 
keratinocytes (KCs) can enhance inflammatory responses 
in AD (10–13) by producing a unique profile of cytokines 
and chemokines (thymic stromal lymphopoietin (TSLP), 
interleukin (IL)-33, chemokine (C-C motif) ligand 27 
(CCL27)) and, in the last decade, the role of KCs in the 
background of skin barrier dysfunction has also been 
highly emphasized (8). 
Filaggrin (FLG) is a skin barrier structural protein 
in the granular and corneal layers of the skin. Com-
mon (R501X and 2282del4) as well as rare (S3247X, 
R2447X and 3702delG) FLG null mutations are crucial 
predisposing factors for AD (14–16). On the other hand, 
inflammatory cytokine and chemokine milieu can also 
impair the skin barrier in severe AD, leading to acquired 
FLG loss by down-regulating the gene expression of 
FLG and profilaggrin-processing enzymes (4, 17). Skin 
barrier function can be equally impaired in patients with 
severe AD irrespective of FLG haploinsufficiency or 
acquired FLG deficiency (18, 19). However, no study 
has investigated whether KC innate immune functions 
differ between patients with genetic FLG loss and pa-
tients with acquired FLG decrease.
The aim of this study was to compare the KC innate 
immune functions, and T-cell and dendritic cell (DC) 
counts in the lesional skin of patients with severe AD 
with genetic or acquired FLG loss.
MATERIALS AND METHODS
Lesional skin biopsies were collected from 24 Caucasian 
patients with severe extrinsic type of AD (20) and from 5 
healthy controls. Two groups were formed according to their 
FLG genotype: patients with severe symptoms without FLG 
mutations (Wt) (n = 12) and patients with severe symptoms with 
FLG mutation (n = 12) (Table I). 5–5 samples in both groups 
were used for immunohistochemistry (IHC) and 12–12 samples 
were analysed by quantitative PCR (qPCR). Detailed patient 
information is given in Appendix S11.
Analysis of the FLG mutations R501X and 2282del4 (21, 22) 
was performed for all patients as previously described (18). A 
detailed protocol is given in Appendix S11.
Paraffin-embedded sections were stained with antibodies 
against human FLG, Ki67, TSLP, IL-33, CCL27, CD3 and 
CD11c. The slides were digitalized and analysed by using Pan-
noramic Viewer 1.15.2 (3DHistech Ltd, Budapest, Hungary) 
software. Detailed protocols are available in Appendix S11.
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Total RNA was isolated and quantified according to the 
manufacturer’s protocol, which are available in Appendix S11.
To determine the statistical significance between the 3 groups, 
one-way analysis of variance (ANOVA) test and Newman-
Keuls post test were used. Differences between the groups were 
demonstrated using mean ± 95% confidence interval. Analysis 
of correlations was performed by Pearson r test. p-values < 0.05 
were considered statistically significant.
RESULTS
Detection of severity markers in the skin of wild type 
and filaggrin mutant severe atopic dermatitis patients
The quantification of 2 histological severity markers, 
namely the measurement of epidermal thickness (ET) 
(not shown) and the detection of Ki67-positive cells 
(Fig. 1b), was performed. No differences were found 
in the levels of these parameters between the 2 AD 
groups (ET: MEAN Wt AD= 159.4 µm; MEAN FLG Mutant 
AD=176.7 µm), but compared with controls ET (HC vs. 
Wt AD: p < 0.001; HC vs. Mutant AD: p < 0.001) and 
Ki67 expression levels (HC vs. Wt AD: p < 0.001; HC 
vs. Mutant AD: p < 0.001) were significantly higher in 
both AD groups. These data corresponded to an almost 
identical clinical severity (OSCORAD) of the patients. 
Immunohistochemistry analyses of keratinocyte-derived 
cytokines, chemokine and filaggrin in the skin of wild type 
and filaggrin mutant severe atopic dermatitis patients 
To demonstrate FLG loss in the skin of the patient 
groups, immunostaining of FLG was performed. No 
difference was found between the levels of FLG in the 
skin of the 2 patient groups and the protein levels were 
significantly lower compared with controls (HC vs. Wt 
AD: p < 0.001; HC vs. Mutant AD: p < 0.001) (Fig. 1a). 
In AD skin, FLG could be detected discontinuously with 
mild positivity; in contrast, FLG was found continually 
with strong positivity in the granular layer of normal 
skin. Quantification of KC-derived proinflammatory cy-
tokines thymic stromal lymphopoietin (TSLP) and IL-33 
and chemokine CCL27 was also carried out. The levels 
of the 2 proinflammatory cytokines and chemokines 
were significantly higher in the skin of patients with AD 
than in the control group, but no differences were found 
between the 2 AD groups (Fig. 1c, d, e) (HC TSLP vs. 
Wt AD TSLP: p < 0.05; HC TSLP vs. Mutant AD TSLP: 
p < 0.01; HC IL-33 vs. Wt AD IL-33: p < 0.01; HC IL-33 
vs. Mutant AD IL-33: p < 0.01; HC CCL27 vs. Wt AD 
CCL27: p < 0.001; HC CCL27 vs. Mutant AD CCL27: 
p < 0.001). It is important to note that TSLP was only 
slightly detectable, or not detectable, in control skin. 
Cytoplasmic positivity of TSLP in AD skin showed 
decreasing intensity from the granular layer towards the 
basal membrane in the epidermis. Strong IL-33 nuclear 
positivity was observed above the basal membrane in 
2–5 cell layers in AD skin. It was expressed moderately 
in the normal skin of healthy control subjects, but only in 
basal KCs. CCL27 expression 2–3 cell layers below the 
granular layer was detectable in control skin samples, 
but was significantly higher in the AD groups. 
Detection of thymic stromal lymphopoietin, IL-33 and 
CCL27 mRNA levels in the skin of wild type and filaggrin 
mutant severe atopic dermatitis patients 
Regarding all the 3 investigated parameters, no signi-
ficant differences could be detected in mRNA levels 
between the 2 AD groups (Table I). Comparing the 
healthy control group with the AD groups, difference 
could be found only regarding IL-33 mRNA levels. 
T cells and dendritic cells in the skin of wild type and 
filaggrin mutant severe atopic dermatitis patients
CD3+ T cells (Fig. 1f) and CD11c+ DCs (Fig. 1g) were 
also immunostained. The number of T cells (HC vs. Wt 
AD: p < 0.001; HC vs. Mutant AD: p < 0.001) and DCs 
(HC vs. Wt AD: p < 0.001; HC vs. Mutant AD: p < 0.001) 
were significantly higher in the skin of patients with AD 
compared with the skin of healthy controls, but there 
were no differences between the skin of the 2 AD groups.
Correlations between histological severity markers and 
keratinocyte-derived cytokines and chemokine, T-cell and 
dendritic cell counts
Since no differences were found with regard to the mea-
sured parameters between the 2 AD groups, all data for 
Table I. Clinical characteristics and quantitative PCR (qPCR) 
data of patients with atopic dermatitis (AD) Significant differences 
were found between the 2 AD groups in total IgE levels and 
frequency of sensitization (*p < 0.05). Other parameters did not 
differ significantly. There were no AD patients with compound 
heterozygous mutation of filaggrin (FLG). qPCR data are presented 
as gene expression relative to controls. No significant differences 
were detected between the 2 AD groups
FLG Wt severe 
AD 
n=12
FLG Mutant 
severe AD 
n=12
FLG mutation 2282del4 0/12 2282del4 9/12
R501x 0/12 R501x 3/12
Age, years, mean ± SD 21 ± 9.98 12.8 ± 7.85
Age at onset, month, mean ± SD 37 ± 41.8 5 ± 7.7
SCORAD, mean ± SD 44.8 ± 8.28 42.6 ± 6.3
Blood eosinophil count, %, mean ± SD 0.87 ± 0.57 0.82 ± 0.53
TEWL, g/m2/h, mean ± SD
Non-lesional skin 29.76 ± 10.59 26.2 ± 12.93
Lesional skin 43.31 ± 4.52 42.39 ± 9.97
Serum total IgE, kU/l*, mean ± SD 2,813.9 ± 1,750.3 8,313.7 ± 6,624.8
Sensitization proven by prick test*, n 6/12 12/12
qPCR results, mean ± SEM
Thymic stromal lymphopoietin 0.51 ± 0.21 0.55 ± 0.14
IL-33 0.10 ± 0.049 0.06 ± 0.008
CCL27 1.87 ± 0.57 1.76 ± 0.64
SCORAD: SCORing Atopic Dermatits; TEWL: transepidermal water loss; 
SD: standard deviation; SEM: standard error of the mean.
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patients with AD were pooled together and immune cell 
counts and levels of KC-derived cytokines and chemo-
kine were correlated with ET, Ki67 expression and FLG 
contents. Statistically significant correlations were found 
between Ki67 and TSLP levels (p = 0.0226; Pearson 
r = 0.7058) (Fig. 2a), between Ki67 and CCL27 levels 
Fig. 1. Expression of (a) filaggrin (FLG), (b) Ki67, (c) thymic stromal lymphopoietin (TSLP), (d) interleukin 33 (IL-33), (e) chemokine (C-C motif) ligand 
27 (CCL27), (f) CD3 and (g) CD11c in normal, Wt severe atopic dermatitis (AD) and FLG mutant severe atopic dermatitis (AD) skin. No difference 
was found between the severe AD groups with regard to all measured parameters. (a) FLG level was significantly decreased in AD groups compared 
with controls (1a); all of the other investigated parameters ((b) Ki67, (c) TSLP, (d) IL-33, (e) CCL27, (f) CD3+T cells, (g) CD11c+DCs) were expressed 
in significantly higher amounts in the skin of patients with AD. Graphs show the mean ± 95% confidence interval of measured protein levels. *p < 0.05; 
**p < 0.01; ***p < 0.001.
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(p = 0.0138; Pearson r = 0.7769) (Fig. 2b), between ET 
and IL-33 levels (p = 0.0430; Spearman r = 0.7222) (Fig. 
2c) and between ET and CD3+ cell count (p = 0.0164; 
Spearman r = 0.7645) (Fig. 2d). No correlations were 
observed between histological severity markers and DC 
count and between FLG levels and severity markers or 
T-cell and DC counts and between OSCORAD and our 
investigated parameters (not shown). 
DISCUSSION
AD is a multifactorial immune-mediated inflammation 
of the skin that is driven by interactions of genetic and 
environmental factors (23). Over-reactive adaptive, 
dysregulated innate immune responses and impaired 
skin barrier functions together lead to the manifestation 
of the disease (24). FLG, a crucial component of the 
physicochemical skin barrier, shows several genetic 
alterations (e.g. copy number variations and FLG null 
mutations) and, together with other less studied barrier 
gene mutations (KLK7, SPINK5 and Claudin-1), can 
predispose to AD (9). On the other hand, acquired bar-
rier dysfunctions can be caused by the frequent usage of 
detergents and exposure to allergens and Staphylococ-
cus (25), as well as by local skin inflammation (18). 
The question as to whether genetic or acquired skin 
barrier dysfunctions can alter KC immune function 
differently has not been raised.
The aim of this study was to determine whether 
immune-mediated skin inflammation (KC function, T-
cell and DC count) differs between severe AD patients 
with or without FLG mutations. We also investigated 
the correlations between histological severity markers, 
FLG content, KC-derived cytokine and chemokine 
levels and T-cell and DC counts. In order to answer 
our questions, 2 patient groups were created: FLG Wt 
patients and FLG mutant patients with severe symptoms 
and matching OSCORAD. Two parameters, ET and 
Ki67 expression, were investigated to score histological 
severity (25–29). Significantly thickened epidermis and 
elevated Ki67 levels were found in the 2 AD groups 
compared with controls, whereas no differences were 
observed between the 2 severe AD groups irrespective 
of their FLG genotype. 
Although serum IgE levels and frequency of sensi-
tization were significantly higher in the FLG mutant 
AD group, the clinical and histological severity were 
the same, and no difference was found in the epidermal 
FLG content. These findings are in concordance with 
our previous results, as the level of FLG loss is con-
nected to the severity of the skin inflammation, rather 
than to the cause of FLG loss, while IgE level and sen-
sitization seem to be connected to FLG genotype with 
significantly increased levels in FLG mutant AD (18).
To study whether immune functions of KCs dif-
fer between severe AD patients with or without FLG 
mutations, TSLP, IL-33 and CCL27 tissue levels were 
compared. In the last few years, the importance of TSLP 
in AD has been highlighted. TSLP is produced by KCs 
and is known for its capacity to induce CD11c+ myeloid 
DCs to promote Th2-skewed inflammatory responses. 
Previous studies have shown significantly elevated se-
rum (30, 31), epidermal (32, 33) and stratum corneum 
(34) TSLP levels in AD compared with controls, while 
other groups failed to detect higher serum TSLP levels 
in these patients. The intensity of expression in the 
stratum corneum correlated with clinical severity (34), 
while, on the contrary, the relationships between serum 
and epidermal TSLP levels and OSCORAD were highly 
controversial (18, 30, 31). In parallel with previous 
data in the literature (31, 32), we found significantly 
higher epidermal TSLP levels in patients with AD than 
in controls; according to our results, TSLP protein 
levels did not differ between Wt and FLG mutant AD 
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Fig. 2. Correlation between histological severity markers 
(Ki67, epidermal thickness (ET)), T-cell count and levels 
of keratinocyte (KC)-derived cytokines and chemokines. 
Statistically significant correlations were found (a) between 
Ki67 and thymic stromal lymphopoietin (TSLP) levels 
(p = 0.0226; Pearson r = 0.7058), (b) between Ki67 and CCL27 
levels (p = 0.0138; Pearson r = 0.7769), (c) between ET and 
interleukin 33 (IL-33) levels (p = 0.0430; Pearson r = 0.7222) 
and (d) between ET and CD3+ cell count (p = 0.0164; Pearson 
r = 0.7645). Analysis of correlations was performed by 
Pearson r test.
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groups. In our study, epidermal TSLP levels correlated 
significantly with the level of the histological severity 
marker Ki67, but no relationship was found between 
TSLP levels and clinical severity.
IL-33, a newly discovered AD-specific cytokine, is 
expressed by epithelial cells and activates Th2 lympho-
cytes, mast cells and eosinophils (35). Our results sho-
wed that IL-33 protein expression was significantly ele-
vated in the AD groups compared with controls and no 
significant difference was found in IL-33 protein levels 
between the Wt and FLG mutant AD patients. These 
data correspond to a previous investigation, which 
found IL-33 protein expression to be up-regulated in 
the lesional skin of patients with AD (35), although 
the comparison of FLG mutant and Wt AD groups was 
not performed in that study. In another investigation, a 
correlation was found between serum IL-33 levels and 
disease severity of AD (36). Our group found a strong 
correlation between ET and levels of epidermal IL-33 
protein, but failed to detect any relationship between 
clinical disease severity and epidermal IL-33 levels.
CCL27 is a skin-specific CC chemokine produced by 
KCs, which contributes to tissue-restricted leukocyte 
trafficking and can induce inflammation by promoting 
the migration of Th2 cells into the skin (37). A previous 
study described strong CCL27 expression in lesional 
keratinocytes of patients with AD by using IHC (38). 
Similarly, we also found significantly elevated protein 
levels of CCL27 in AD skin, but when Wt and FLG 
mutant AD groups were compared, no difference was 
detected. Serum CCL27 level was found to correlate 
significantly with OSCORAD in patients with AD by a 
Japanese group (38), but no data have been published 
about the relationship between the epidermal levels of 
CCL27 and disease severity. Significantly correlated 
expression levels of CCL27 and Ki67 were found by our 
group, but no relationship could be detected between 
tissue CCL27 levels and OSCORAD. 
Our IHC results were also confirmed by qPCR analy-
ses, since TSLP, IL-33 and CCL27 mRNA levels were 
similar in the 2 AD groups. In the literature no qPCR 
data can be found comparing FLG mutant and WT AD 
groups regarding these parameters, but a recent RNA 
sequencing investigation could indirectly strengthen 
our results, as these cytokines were not published in 
the list of differentially expressed (fold change ≥ 2 and 
p < 0.05) genes (39). Comparing healthy controls with 
patients with AD, mRNA levels did not reflect the de-
tected protein levels. This contrast can be explained by 
post-transcriptional modification, namely the regulation 
of mRNA degradation and translation by enzymes and 
micro RNAs, which depends on the actual state of the 
keratinocytes and systemic needs. To date, only 2 artic-
les have been published on the mRNA levels of TSLP 
and IL-33 (31, 35) and none on CCL27 gene expression 
in patients with AD. The differences found in the rela-
tionship between the clinical and histological severity 
markers and KC-derived proinflammatory cytokines 
(TSLP, IL-33) and chemokine (CCL27) highlights the 
fact that using OSCORAD is not always parallel to the 
degree of inflammation in a given plaque; therefore, 
the local immune markers of inflammation presumably 
show better correlation with a local severity marker than 
a complete skin severity marker.
Since the aforesaid cytokines and chemokine pro-
duced by KCs have an effect on T cells and DCs (10), 
their cell counts were assayed. In our investigation, 
similar to a previous study (40), the number of T cells 
and DCs were found to be significantly higher in the 
skin of patients with severe AD compared with the skin 
of healthy controls. We found no significant differen-
ces between the immune cell numbers of FLG mutant 
and Wt AD patient groups. We also detected a strong 
correlation between ET and CD3+ T-cell count. On the 
other hand, DC count showed no direct connection with 
AD histological severity markers and our workgroup 
did not find any correlation between FLG content and 
all of the investigated parameters.
In conclusion, our results suggest that immune-
mediated skin inflammation, represented by innate and 
adaptive immune cell counts and KC-derived cytokine 
and chemokine content, does not differ between severe 
AD patients with acquired or genetically determined 
FLG loss. This may indicate that genetic FLG muta-
tion in KCs does not influence the immune function 
of these cells in a different manner. The results of the 
correlations demonstrated that immune activation in the 
skin is connected to the severity of the disease rather 
than to the origin of barrier alterations.
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